Your browser doesn't support javascript.
loading
Latent and active tuberculosis infection in allogeneic hematopoietic stem cell transplant recipients: a prospective cohort study.
de Oliveira Rodrigues, Marina; de Almeida Testa, Lucia H; Dos Santos, Ana Cláudia F; Zanetti, Lilian P; da Silva Ruiz, Luciana; de Souza, Mair Pedro; Colturato, Vergílio R; Machado, Clarisse M.
Afiliação
  • de Oliveira Rodrigues M; Universidade Paulista UNIP - Instituto de Ciências da Saúde, Bauru, Brazil.
  • de Almeida Testa LH; HSCT Program - Amaral Carvalho Foundation, Jaú, Brazil.
  • Dos Santos ACF; HSCT Program - Amaral Carvalho Foundation, Jaú, Brazil.
  • Zanetti LP; HSCT Program - Amaral Carvalho Foundation, Jaú, Brazil.
  • da Silva Ruiz L; Centro de Laboratórios Regionais, Instituto Adolfo Lutz - Bauru II, São Bauru, Brazil.
  • de Souza MP; HSCT Program - Amaral Carvalho Foundation, Jaú, Brazil.
  • Colturato VR; HSCT Program - Amaral Carvalho Foundation, Jaú, Brazil.
  • Machado CM; HSCT Program - Amaral Carvalho Foundation, Jaú, Brazil. clarimm@usp.br.
Bone Marrow Transplant ; 56(9): 2241-2247, 2021 09.
Article em En | MEDLINE | ID: mdl-33966056
Tuberculosis (TB) is a major infectious complication in hematopoietic stem cell transplant (HSCT) recipients in countries with high TB prevalence. Identifying and treating latent tuberculosis infection (LTBI) helps to prevent TB reactivation after transplantation. Few studies have compared the tuberculin skin test (TST) with interferon Gamma release assays (IGRA) to diagnose LTBI in HSCT candidates. We compared TST and QuantiFeron TB gold in tube (QTF-GIT) and prospectively evaluated the incidence of active tuberculosis in 126 HSCT candidates and 58 HSCT recipients with chronic GVHD followed at the outpatient clinic. TB was diagnosed by culture in Mycobacteria media and by commercial real-time PCR kit. Considering the positivity of any test, the prevalence of LTBI was 8.7% in HSCT candidates (11 out of 126) and 12.5% in HSCT recipients with chronic GVHD (6 out of 48). QTF-GIT indeterminate results were detected in 2.4% of the HSCT candidates. Fair to good agreement (K > 0.50) between tests was observed in both cohorts. Cumulative incidence of TB was 3% in the GVHD cohort. TB was diagnosed in 2 chronic GVHD recipients, both cases confirmed by positive culture and PCR. None of the 11 patients with LTBI diagnosed pre-HSCT who received INH prophylaxis developed TB.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Bone Marrow Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Bone Marrow Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido